Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Victoza® becomes the first and only GLP-1 receptor agonist (GLP-1 RA) in the UK shown to reduce the risk of cardiovascular (CV) events

Novo Nordisk Ltd
Posted on: 16 Aug 17

Victoza® becomes the first and only GLP-1 receptor agonist (GLP-1 RA) in the UK shown to reduce the risk of cardiovascular (CV) events, in addition to lowering blood sugar and reducing weight, in adults with type 2 diabetes1,2

Gatwick, UK, 11 August 2017 — The European Commission has approved an expansion to the Victoza® (liraglutide up to 1.8 mg) EU label which reflects both improving blood glucose and cardiovascular (CV) events as integral parts of type 2 diabetes (T2D) treatment1. As demonstrated in the landmark LEADER trial, liraglutide (up to 1.8 mg) is the first and only GLP-1 receptor agonist (GLP-1 RA) shown to reduce the risk of cardiovascular (CV) events, in addition to lowering blood sugar and reducing weight, in adults with type 2 diabetes1,2.

"For the majority of type 2 diabetes patients I see, how to minimise their risk of heart attack, stroke and cardiovascular disease is a serious consideration for their long-term health," says Professor Steve Bain, UK LEADER trial National Leader and Assistant Medical Director for Research & Development for ABM University Health Board and Clinical Lead for the Diabetes Research Unit, Wales. "Cardiovascular disease is the leading cause of mortality in patients with diabetes, accounting for almost two out of three diabetes-related deaths."

"I welcome the expansion to the liraglutide 1.2 mg and 1.8 mg label to reflect it's demonstrated benefits in reducing this cardiovascular disease risk in the type 2 diabetes population," continues Professor Bain. "From a clinician’s perspective, we are often focused, rightly or wrongly, on controlling blood sugar levels. Now when we choose which treatment to prescribe we have an option that is proven to be effective not only in lowering blood sugar levels and reducing weight, but in improving the cardiovascular outcomes of our patients with diabetes that are at such increased risk compared to the average population."

People with T2D are at a 2–4 times higher risk of CV disease than the general population3. Furthermore, it is the most costly complication of diabetes4.

The updated label includes results from the LEADER trial, which demonstrated that liraglutide (up to 1.8 mg) is superior in preventing major CV events (CV death, non-fatal heart attack or non-fatal stroke) by 13% versus placebo, (95% confidence interval [CI]: 0.78; 0.97, p=0.01) when added to standard of care in people with type 2 diabetes and at high CV risk2. This result was primarily driven by a significant 22% (95% CI: 0.66; 0.93, p=0.007) reduction in CV death2.

References
1. EMA. Victoza® (liraglutide) Summary of Opinion (post authorisation). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/001026/WC500229898.pdf. Last accessed: August 2017.
2. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;374:311-322.
3. Fowler MJ. Microvascular and macrovascular complications of diabetes Clin Diabetes. 2008;26:77-82.
4. Hex N, Bartlett C, Wright D, et al. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012 Jul;29(7):855-62.
5. EMA. Victoza® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001026/WC500050017.pdf. Last accessed: August 2017.
6. Internal Calculations based on IMS Midas Quantum data. December 2016.

For more information:
www.novonordisk.co.uk

Editor's Details

Novo Nordisk Victoza
Novo Nordisk Victoza
www.novonordisk.co.uk

Last updated on: 16/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.